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Abstract
Background: Annual seasonal influenza outbreaks are associated with high morbidity and mortality.
Objective: To index and document evolutionary changes among influenza A H1N1 and H3N2 viruses isolated from Thailand
during 2006–2009, using complete genome sequences.
Methods: Nasopharyngeal aspirates were collected from patients diagnosed with respiratory illness in Thailand during
2006–2009. All samples were screened for Influenza A virus. A total of 13 H1N1 and 21 H3N2 were confirmed and whole
genome sequenced for the evolutionary analysis using standard phylogenetic approaches.
Results: Phylogenetic analysis of HA revealed a clear diversification of seasonal from vaccine strain lineages. H3N2 seasonal
clusters were closely related to the WHO recommended vaccine strains in each season. Most H1N1 isolates could be
differentiated into 3 lineages. The A/Brisbane/59/2007 lineage, a vaccine strain for H1N1 since 2008, is closely related with
the H1N1 subtypes circulating in 2009. HA sequences were conserved at the receptor-binding site. Amino acid variations in
the antigenic site resulted in a possible N-linked glycosylation motif. Recent H3N2 isolates had higher genetic variations
compared to H1N1 isolates. Most substitutions in the NP protein were clustered in the T-cell recognition domains.
Conclusion: In this study we performed evolutionary genetic analysis of influenza A viruses in Thailand between 2006–2009.
Although the current vaccine strain is efficient for controlling the circulating outbreak subtypes, surveillance is necessary to
provide unambiguous information on emergent viruses. In summary, the findings of this study contribute the
understanding of evolution in influenza A viruses in humans and is useful for routine surveillance and vaccine strain
selection.
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Introduction
Influenza A viruses are negative-strand RNA viruses of the
family Orthomyxoviridae which can be divided into subtypes based on
the antigenic properties of the surface glycoproteins, hemaggluti-
nin (HA) and neuraminidase (NA) [1]. Every year influenza A
virus causes infection with varying severity depending on host
acquired immunity against that particular virus strain. Influenza
epidemics are associated with above average annual mortality
levels, causing 10,000 to 15,000 deaths. Occasionally global
pandemics of influenza occur, infecting 20% to 40% of the
population in a single year and dramatically raising death rates.
Three such major global pandemics caused by novel antigenic
variants of influenza viruses have affected the human population:
in 1918 (H1N1 subtype), in 1957 (H2N2), and in 1968 (H3N2)
resulting in millions of deaths [2,3]. The recent circulation of
highly pathogenic avian H5N1 viruses in Asia since 2003 has
caused human fatalities [4]. The novel H1N1 influenza virus that
emerged in humans in Mexico in early 2009 and spread globally in
the human population has been declared a pandemic strain.
Two forms of the 16 possible HA subtypes (H1 and H3), and
two of the nine possible NA subtypes (N1 and N2) are circulating
in man. H3N2 and H1N1 influenza A viruses have co-circulated
in the human population since the re-emergence of H1N1 in 1977
increasing the possibility of genetic reassortment. The prevalence
of different subtype combinations may vary from season to season.
Subtype H3N2 has constituted the predominant influenza A strain
during the last 20 years, with the exception of the 1988–1989 and
2000–2001 seasons when H1N1 infections were more prevalent
[5]. The surface glycoprotein HA is under selective pressure to
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Antibodies against the HA protein inhibit receptor binding and
are very effective at preventing re-infection with the same strain.
However, HA can change to evade previously acquired immunity
either by antigenic drift, whereby mutations of the currently
circulating HA gene disrupt antibody binding, or by antigenic
shift, with the virus acquiring an HA of a new subtype by re-
assortment of one or more gene segments. The WHO has
published recommendations on the composition of influenza
vaccine for the northern and southern hemispheres. For the
northern hemisphere, the WHO has issued the recommendation
for strains to be included in the trivalent vaccine for the next
season based on epidemiological data and genetic analyses of
circulating strains.
The ability to predict emergence of circulating influenza strains
for subsequent annual vaccine development has become vital.
Comparisons between antigenic differences and phylogenetic
analysis are essential to further the understanding of emergence
of multiple lineages of influenza virus variants. Therefore, the aim
of this study is to elucidate the evolution of influenza A H1N1 and
H3N2 isolates from Thailand over a four years time period early
2006 to 2009. Understanding of viral genome content and its
evolution is experted to aid in predicting the emergence of new
variant strains during the following season and defining the
vaccine composition.
Results
Specimens were collected from patients diagnosed with
respiratory illness in Bangkok, Thailand from 2006 to 2009.
Clinical specimens were screened for influenza A virus by
multiplex real-time PCR and then subtyped as H1 or H3 with
specific primers. Of the influenza A virus positive samples,
21H3N2 and 13 H1N1 samples were selected to represent each
time-point, respectively. The HA and NA sequences of some
strains isolated in 2006 to 2007 have been previously reported
[13]. The details are shown in Table 1. (accession numbers are
provided in supporting information Table S1).
Five H1N1 isolates from the 2006 season and eight isolates from
2009 were compared with the vaccine strains for phylogenetic
associations. H1 phylogeny showed that the isolates clustered in 3
distinct lineages (Fig. 1). First, the HA of A/Thailand/CU32/
2006 was closely related to the A/NewCaledonia/20/1999 lineage
(vaccine strain for 2007 Southern Hemisphere) by 97.84% and
98.21% based on nucleotide and amino acid similarity, respec-
tively. Second, four isolates from 2006 were closely related to the
A/Solomon Island/3/2006 lineage (vaccine strain for 2007–2008
Northern Hemisphere). The average percent nucleotide and
amino acid identities of HA to this vaccine strain are 98.67%
and 98.25%, respectively. Last, the phylogenetic tree of H1
showed that five isolates from 2009 were closely related with A/
Brisbane/59/2007 like lineage (vaccine strain for 2008–2009
Northern Hemisphere, 2009 Southern Hemisphere and 2009–
2010 Northern Hemisphere). These similarities between isolates
and vaccine strain lineage were slightly different at 99.25% and
99.24% based on nucleotide and amino acid sequences,
respectively.
Twenty one HA sequences of H3N2 isolates were compared
with vaccine strains (Fig. 2). The results showed that H3 nucleotide
sequences formed seasonal phylogenetic clusters representative for
the 2005–2006, 2006–2007, 2007–2008 and 2009 seasons. The
H3 nucleotide sequences of the 2005–2006 season were closely
related to the A/Wisconsin/67/2005 like lineage (vaccine strain
for 2006–2007 Northern Hemisphere, 2007 Southern Hemi-
sphere, 2007–2008 Northern Hemisphere). The average nucleo-
tide similarity of HA to this vaccine strain is 99.49% and 98.53%
based on amino acids sequences. The 2006–2007 strains were
distinct from the 2005–2006 strains. The average nucleotide
similarities among the 2006–2007 and 2005–2006 strains were
99.029% (98.88% based on amino acids) and similarities of the
2006–2007 strain to the A/Wisconsin67/2005 like lineage
decreased to 98.985% (97.64% based on amino acids). During
the following season, 2007–2008, the H3 nucleotide sequence had
drifted more towards A/Brisbane/10/2007 like lineage (vaccine
strain for 2008 Southern Hemisphere, 2008–2009 Northern
Hemisphere, 2009 Southern Hemisphere and 2009–20010
Northern Hemisphere) (99.392% and 99.24% similarity based
on nucleotide and amino acids sequences, respectively).
The H3 nucleotide sequences of the 2009 virus isolates had
drifted from the the 2007–2008 strain. These strains were unique
to the 2009 season. The nucleotide similarities between the 2009
and 2007–2008 strains were 98.98% (98.86% based on amino
acids); between the 2009 strains and the A/Brisbane/10/2007 like
lineage they decreased to 98.83% (98.62% based on amino acids).
The viruses from this season were closely related to the A/Perth/
16/2009-like lineage (vaccine strain for 2010 Southern Hemi-
sphere). The nucleotide identities between the 2009 strains and the
A/Perth/16/2009-like lineage were 99.64% and 99.36% based on
amino acids.
Amino acid sequences of circulating strains were compared to
the vaccine strains in order to highlight functional variation that
might potentially impact vaccine efficacy. HA constitutes the
receptor-binding and membrane fusion glycoprotein of influenza
virus. Alignment of the terminal sialic acid (SA) residues of
glycoproteins and glycolipids representing the cellular receptors for
influenza virus, which are the targets for neutralizing antibodies,
and the conserved N-linked glycosylation sites are shown in Fig. 3
and Fig. 4. The conserved amino acid residues in both H1 and H3
influenza A virus, Tyr(Y)-98, Ser(S)-136, Trp(W)-153, His(H)-183
and Tyr(Y)-195 (numbering according to H3 structure) at the HA
receptor-binding site have been described by Skehel and Wiley
[14]. These residues were found at the HA receptor binding site of
both H1N1 and H3N2. The residues mainly responsible for
NeuAca2,6Gal linkage of H3 are at positions 226 and 228. Amino
acids at the terminal SA of all H3 isolates were Ile(I)-226 and
Ser(S)-228, similar to those previously reported by Lindstrom et al.
[15]. N-linked glycosylation was commonly found in HA. As for
HA1 of the H1 subtype, the seven positions of potential N-
glycosylation, with a threshold value of .0.5, were predicted (at
positions 15, 27, 58, 91, 129, 164 and 290). These sites were found
to be conserved among all isolates in this study. Nine potential N-
glycosylation sites were predicted in HA1 of the H3 subtype (at
positions 8, 22, 38, 63, 126, 133, 165, 246 and 285) with a
threshold value of .0.5. These sites were found to be conserved
among all isolates obtained during 2006–2009. In comparison
with the 2005–2006 strain, the majority of 2006–2007 viruses had
lost the predicted glycosylation at position 144; one isolate showed
glycosylation at this position (A/Thailand/CU231/2006). The
predicted score at position 144 has been under the set threshold
value of 0.5 and was therefore not included in this analysis. All
isolates from the 2007–2008 and 2009 seasons had lost this
position.
The HA1 domain of HA, the major antigenic protein of
influenza A viruses, contains all the antigenic sites of HA and is
continually under selection pressure driven by the host’s immune
response. Patterns of antigenic site variations in the HA gene were
observed by amino acid alignment. H1N1 antibodies are directed
to each of the two strain-specific (Sa and Sb) and common
Human Influenza A Virus
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As for H3, the altered amino acids differences were detected at
antigenic sites A, B, D and E (Fig. 4) Based on amino acid
comparison between circulating strains and vaccine strains, the
2005–2006 strains were closely related to the A/Wisconsin67/
2005 like lineage vaccine. Although some strains of 2007–2008
had altered amino acid residues at antigenic sites in comparison
with the A/Brisbane/10/2007 like lineage, the circulating 2007–
2008 strains were closely related to this vaccine subtype. In
contrast, the 2009 strains showed variations at 8 positions in HA1
compared to the A/Brisbane/10/2007 like lineage vaccine,
including 6 positions at the antigenic site: N/K-144 at site A;
N/K-158 and K/N-189 at site B; Q/K-173, R/Q-261 at site E;
and A/T-212 at site D. On the other hand, the 2009 strains
showed three altered amino acids at the antigenic site when
compared to the A/Perth/16/2009-like lineage; S/I-214 at site D;
T/A-212 at site D and R/Q-261 at site E.
Alteration at positions prone to induce drug resistance were
observed. Oseltamivir resistance associated mutation at position
274 of NA was absent n all H3N2 isolates between 2006 and 2009
and H1 isolates from 2006. In contrast, all H1N1 isolates from
2009 exhibited the oseltamivir resistant amino acid, Y, at position
274 of the NA protein. The S31N substitution in the M2 protein
indicates resistance to amantadine, the influenza matrix ion
channel inhibitory drug. Five H3N2 isolates from the 2006–2007
seasons (A/Thailand/CU228/2006, A/Thailand/CU231/2006,
A/Thailand/CU260/2006, A/Thailand/CU280/2007 and A/
Thailand/CU282/2007) displayed Serin (S) at this position
indicating amantadine sensitivity. But in the 2007–2009 H3N2
strain, this position had changed to Asparagine (N) implying drug
resistance. Only one isolate from 2009 (A/Thailand/CU-H223/
2009) displayed Asparagine at this position (amantadine resistance
genotype) while all H1N1 isolates showed amantadine sensitive
associated genotype.
Table 1. The details of the specimens.
Subtype Strain Date Sex Age Seasonal cluster
H1N1 A/Thailand/CU32/2006 13-04-2006 Female 3 years A/NewCaledonia/20/1999 lineage
A/Thailand/CU44/2006 13-05-2006 Female 11 years A/Solomon Island/3/2006 lineage
A/Thailand/CU51/2006 30-05-2006 Male 2 years A/Solomon Island/3/2006 lineage
A/Thailand/CU68/2006 26-06-2006 Female 8 months A/Solomon Island/3/2006 lineage
A/Thailand/CU88/2006 25-07-2006 Female 5 months A/Solomon Island/3/2006 lineage
A/Thailand/CU-B42/2009 16-06-2009 Male 39 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-H17/2009 18-06-2009 Female 34 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-B97/2009 22-06-2009 Male 22 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-B267/2009 02-07-2009 Female 33 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-B589/2009 10-07-2009 Male 43 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-B685/2009 12-07-2009 Female 45 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-H223/2009 17-07-2009 Female 36 years A/Brisbane/59/2007 like lineage
A/Thailand/CU-H565/2009 02-09-2009 Female 60 years A/Brisbane/59/2007 like lineage
H3N2 A/Thailand/CU23/2006 22-03-2006 Female 1 year 2005–2006 season
A/Thailand/CU46/2006 18-05-2006 Male 11 months 2005–2006 season
A/Thailand/CU228/2006 11-10-2006 Male 2 years 2006–2007 season
A/Thailand/CU231/2006 14-11-2006 Male 1 year 2006–2007 season
A/Thailand/CU260/2006 27-12-2006 Female 1 year 2006–2007 season
A/Thailand/CU280/2007 26-01-2007 Female 2 years 2006–2007 season
A/Thailand/CU282/2007 02-02-2007 Male 3 years 2006–2007 season
A/Thailand/CU1101/2008 25-02-2008 Female 3 years 2007–2008 season
A/Thailand/CU1102/2008 20-03-2008 Male 3 years 2007–2008 season
A/Thailand/CU1103/2008 24-03-2008 Male 10 years 2007–2008 season
A/Thailand/CU356/2008 25-03-2008 Male 11 months 2007–2008 season
A/Thailand/CU370/2008 16-06-2008 Male 5 months 2007–2008 season
A/Thailand/CU379/2008 04-07-2008 Female 9 months 2007–2008 season
A/Thailand/CU-B4/2009 13-06-2009 Female 5 years 2009 season
A/Thailand/CU-H16/2009 17-06-2009 Female 22 years 2009 season
A/Thailand/CU-B106/2009 22-06-2009 Male 7 years 2009 season
A/Thailand/CU-B110/2009 23-062009 Male 8 years 2009 season
A/Thailand/CU-B590/2009 10-07-2009 Female 40 years 2009 season
A/Thailand/CU-B657/2009 11-07-2009 Female 29 years 2009 season
A/Thailand/CU-B1672/2009 30-10-2009 Female 22 years 2009 season
A/Thailand/CU-B1697/2009 10-11-2009 Female 59 years 2009 season
doi:10.1371/journal.pone.0009717.t001
Human Influenza A Virus
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HLA epitope. Details concerning alteration of the HLA epitope
are shown in supporting information Table S2. Most substitutions
in the T cell epitope were found in the NP protein of both H1N1
and H3N2 viruses. The substitutions were variable by season or
year of collection.
Some amino acid of the isolates had undergone variations
between two successiveseasons demonstrating progressive evolution
in each proteins segment. Except for the NS1 protein, HA and NA
displayed more variations per season than other proteins (Fig. 5).
The 2009 viruses had fewer variations in the internal proteins
compared to the 2007–2008 isolates. On the other hand, the HA of
2009 viruses displayed 1.66% amino acid difference compared to
viruses circulating during the previous season. Unfortunately,
H1N1 isolates between 2007 and 2008 were not included in this
study.Basedonamino acid distancecomparison of3 lineage strains,
A/NewCaledonia/20/1999 lineage strain, A/Solomon Island/3/
2006 lineage strains, and 2009 A/Brisbane/59/2007 lineage strain,
was determined in Fig. 6. Most amino acid differences between
lineages were identified in the surface proteins, HA and NA. As for
the internal proteins, NS1 also demonstrated remarkable amino
acid variation between lineages. In contrast, NP had undergone the
least umber of alterations of all 8 proteins compared.
Discussion
Each year, WHO recommends the most suitable composition of
influenza vaccine strains for the Northern and Southern Hemi-
spheres, based on phylogenetic analyses of HA and antigenic
characteristics of circulating viruses. Accordingly, genetic compar-
ison of the HA sequences determined in this study and vaccine
strains showed seasonal clusters are closely related to the vaccine
strains recommended. H3N2 isolates from the 2005–2006 seasons
are closely related to the vaccine strains recommended for 2006–
2007 Northern Hemisphere, 2007 Southern Hemisphere and
2007–2008 Northern Hemisphere (A/Wisconsin/67/2005 like
lineage). During the 2007–2008 seasons, viruses had drifted towards
the sequence of a vaccine strain for 2008 Southern Hemisphere,
2008–2009 Northern Hemisphere and 2009–2010 Northern
Hemishphere (A/Brisbane/10/2007 like lineage). Viruses isolated
from2009arecloselyassociatedwiththeA/Perth/16/2009(H3N2)
like lineage. The A/Perth/16/2009 like lineage represents the most
Figure 1. Phylogenetic tree of H1. The trees were constructed by the Neighbor-Joining method with bootstrap support by 1,000 replicates. (N
represents isolates from this project and o represents vaccine strain).
doi:10.1371/journal.pone.0009717.g001
Human Influenza A Virus
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season.WHOhadrecommended the three lineagestrainsfor2006–
2009, the time perod during which the strains had been circulating.
The evolutionary rate of H3 is rather high with approximately 1.3–
1.8% allelic variation in HA per year.
In contrast, the H1N1 viruses exhibit slow genetic evolutionary
rates. The temporal genetic variations we identified were minor.
Thus, at the time this study was being performed (2006–2009),
only two vaccines were recommended by WHO - A/Brisbane/
59/2007 like lineage vaccine and the A/California/7/2009
(H1N1)-like virus [17]. Given the lower rate of change in H1N1
viruses, these vaccines would be expected to confer protection
against H1N1 viruses that were recovered from clinical cases in
2009. Although, the rate of genetic change of seasonal H1N1
viruses are not as rapid as that identified in H3N2, further
surveillance studies are required.
Figure 2. Phylogenetic tree of H3. The trees were constructed by the Neighbor-Joining method with bootstrap support by 1,000 replicates. (N
represents isolates from this project and o represents vaccine strain).
doi:10.1371/journal.pone.0009717.g002
Human Influenza A Virus
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might be due to its receptor-binding properties and being targeted
by neutralizing antibodies since it represents the membrane fusion
glycoprotein of influenza virus. The residues within the receptor-
binding site are relatively conserved but the residue mainly
responsible for NeuAca2,6Gal linkage specific for the H3 subtype
was Ile226 in the place of Leu226 [18]. In H3, amino acid
substitutions were detected at three antigenic sites, A, B and E.
The antigenic site position preferred for mutation was located at
site A. Positions in the H1N1 isolates differentiating them from the
A/Solomon Island/3/2006 like lineage and A/Brisbane/59/2007
like lineage were part of the antigenic Sa site. Oligosaccharides in
the HA surface proteins might more readily facilitate viral escape
from the immune system than single amino acid changes at the
antigenic sites. Oligosaccharides may trigger conformational
changes in the molecule and mask antigenic sites, which in turn
would prevent binding of host antibodies. The predicted N-linked
glycosylation at position 144 of the HA antigenic site A has not
been observed since the 2006–2007 season. This position may not
play any major role in escape from the immune system.
T-cell epitopes in internal proteins of influenza A virus are more
conserved than antibody epitopes. The reason for this higher
degree of conservation is that 80% of the antibody epitopes are
located in the variable glycoproteins HA and NA, while only 40%
of the T-cell epitopes are found in these proteins [19]. Most
substitutions in regions involved in protective T-cell response were
detected in the NP protein, as most T-cell epitopes are defined for
the NP protein and this protein constitutes the main target for the
host’s cytotoxic immune response [20,21].
During the 2008–2009 season, prevalence of oseltamivir
resistance was very high among isolates from over 30 countries
[22]. In this study, oseltamivir resistance was detected in H1N1
viruses from 2009 strains. The amantadine drug resistant H3N2
viruses increased during the 2007–2009 season in Thailand, while
the most of H1N1was sensitive to amantadine.
Complete genome analysis of human influenza A viruses was
necessary to obtain a comprehensive picture of virus evolution.
The genetic make-up of influenza A viruses changes every year.
Hence, continuous antigen and genome sequence surveillance of
i n f l u e n z aAv i r u s e si ss t i l lar e q u i r e m e n t .I nt h i ss t u d y ,o u r
Figure 3. Amino acid comparison between HAl domains of H1N1 isolates and vaccine strains. Dots represent amino acids similar to the
consensus. The conserved amino acid residues at the receptor-binding site are shown as small rectangles. Alternative amino acids for sialic acid
linkages of HA are underlined. The amino acid residues mapped at previously defined antigenic sites are shown as follows: site Sa (%), site Sb (e), site
Ca (m), and site Cb (N).The the potential N-glycosylation sites, with threshold value of .0.5, are double-underlined. 2009 represents the circulating
strain in 2009 which belong to A/Brisbane/59/2007-like lineage. 2006S represents the circulating strain in 2006 which belong to A/Solomon Island/3/
2006-like lineage. 2006N represents the circulating strain in 2006 which belong to A/New Caledonia/20/1999-like lineage.
doi:10.1371/journal.pone.0009717.g003
Human Influenza A Virus
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Thailand strains and vaccine strains provided by WHO. We
detected significant numbers ofamino acid substitutions in
surface proteins and some in the internal proteins of viruses,
which circulated in Thailand over a period of years (2006–
2009).
Materials and Methods
Clinical samples
All Influenza A virus positive samples obtained during the
patients’ routine examination or treatment were chosen and
stored at 270uC for further analysis. All the patient identifiers
Figure 4. Amino acid comparison between HAl domains of H3N2 isolates and vaccine strains. Dots represent amino acids similar to the
consensus. The conserved amino acid residues at the receptor-binding site are shown as small rectangles. Alternative amino acids for sialic acid
linkages of HA are underlined. The amino acid residues mapped at previously defined antigenic sites A–E are shown as large rectangles. The the
potential N-glycosylation sites, with threshold value of .0.5, are double-underlined.
doi:10.1371/journal.pone.0009717.g004
Human Influenza A Virus
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lity.Patient consent was practically impossible to obtain. Howev-
er, permission was granted by the director of the hospital for
inclusion of these samples in the study. An ethics committee at
the Faculty of Medicine, Chulalongkorn University, Bangkok,
Thailand approved all study protocols. An IRB approval was
obtained under certification reference number COA No. 287/
2008 and IRB No. 391/51, for this study. In addition, all
specimens were used exclusively for academic research and the
patients were not remunerated. Nasopharyngeal aspirates were
randomly selected from the seasonal influenza A positive
specimens from the routine clinical service during 2006–2009.
All samples were tested for influenza A virus subtypes H1 and H3
using a one-step multiplex real-time RT-PCR as described [7].
Specimens positive for pandemic influenza A H1N1 2009 were
excluded from this study.
Figure 5. The trend of H3N2 protein distance. Distance means were computed as the arithmetic mean of all pair wise distances between two
seasons.
doi:10.1371/journal.pone.0009717.g005
Figure 6. The trend of H1N1 protein distance. Distance means were computed as the arithmetic mean of all pair wise distances between two
lineages. 2009 represents the circulating strain in 2009 which belong to A/Brisbane/59/2007-like lineage. 2006S represents the circulating straini n
2006 which belong to A/Solomon Island/3/2006-like lineage. 2006N represents the circulating strain in 2006 which belong to A/New Caledonia/20/
1999-like lineage.
doi:10.1371/journal.pone.0009717.g006
Human Influenza A Virus
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Viral RNA was extracted from 200-ml nasopharyngeal aspira-
tion samples by Real Genomics Viral Nucleic Acid Kit (RBC
Bioscience, Taiwan). cDNA was synthesized at 37uC for 3 hours
using the M-MLV reverse-transcription system (Promega, Madi-
son, WI) and 1 mM universal primer as described by Hoffmann et
al [8]. The whole genome sequences were amplified using the
primer sets for human H1N1 and H3N2 influenza A virus (primer
sequences are available on request). Briefly, 1 ml of cDNA
template was added to the reaction mixture containing 10 mlo f
2.5X Eppendorf mastermix (Eppendorf, Hamburg, Germany),
0.5 mM forward and reverse primers and nuclease free water to a
final volume of 25 ml. Amplification was performed in a thermal
cycler (Eppendorf, Germany) under the following conditions:
Denaturation at 94uC for 3 min, followed by 40 amplification
cycles consisting of denaturation at 94uC for 30 sec, primer
annealing at 50uC for 30 sec (for PB2, PB1, PA genes) and 55uC
for 30 sec (for HA, NP, NA, MP, NS genes) followed by extension
at 72uC for 90 sec, and concluded by a final extension at 72uC for
7 min. After amplification, electrophoresis was carried out in
ethidium bromide containing 2% agarose gels and visualized on a
UV trans-illuminator. PCR products were gel-purified using the
Perfectprep Gel Cleanup kit (Eppendorf, GmbH, Germany). DNA
sequencing (primer sequences on request) was performed by First
BASE Laboratories Sdn Bhd (Selangor Darul Ehsan, Malaysia).
Phylogenetic analysis
Nucleotide sequences were aligned with ClustalX v1.83 [9].
Dendrograms were constructed using the Neighbor-joining (NJ)
approach implemented in MEGA 4 [10]. Bootstrap support for
tree topologies was accomplished using NJ methods implemented
in MEGA with 1,000 iterations. Genetic distances based on NJ
phylogenetic trees were calculated applying Kimura’s two-
parameter method using MEGA 4.
Prediction of N-Glycosylation
Potential N-glycosylation sites (amino acids Asn-X-Ser/Thr,
where X is not Asp or Pro) were predicted using nine artificial
neural networks with the NetNGlyc server 1.0 [11]. A threshold
value of .0.5 average potential score was set to predict
glycosylated sites. The N-Gly-cosite prediction tool at Los Alamos
[12] was used to visualize the fraction of isolates possessing certain
glycosylation sites along the aligned sequences.
Supporting Information
Table S1 Accession number of influenza virus that isolated from
this study.
Found at: doi:10.1371/journal.pone.0009717.s001 (0.07 MB
DOC)
Table S2 Amino acid alterations in HLA epitope in internal
protein. Alterative amino acids in red and brackets indicate the
minor amino acid substitutions.
Found at: doi:10.1371/journal.pone.0009717.s002 (0.05 MB
DOC)
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